Substituted imidazo[1,2-c]quinazolines as A2A antagonists
US11498923B2 · kind B2 · utility
0Cited by
10References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 10, 2018 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Dec 10, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.